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Objective: To assess the efﬁcacy of adalimumab in patients with erosive hand osteoarthritis (OA).
Method: Patients >50 years old, meeting the American College of Rheumatology (ACR) criteria for hand
OA, with pain >50 on 100 mm visual analogue scale (VAS), morning stiffness >30 min and 1 erosive
joint on X-ray with synovitis present on magnetic resonance imaging (MRI) were included in a rando-
mised double-blind placebo-controlled crossover trial. Patients were randomised to adalimumab (40 mg
subcutaneous injections every other week) or identical placebo injections for 12 weeks followed by an 8-
week washout and then crossed over treatment groups for another 12 weeks. The primary outcome was
change in VAS hand pain over 12 weeks. Secondary outcomes included change in Australian/Canadian
Hand OA Index (AUSCAN) pain, function and stiffness subscales from baseline to 4, 8 and 12 weeks,
change in MRI-detected synovitis and bone marrow lesions (BMLs) from baseline to 12 weeks and
change in VAS from baseline to 4 and 8 weeks.
Results: We recruited 51 patients and 43 were randomised to either Group 1 (N ¼ 18, active then pla-
cebo) or Group 2 (N ¼ 25, placebo then active). At 12 weeks there was no difference between the groups
on the primary outcome measure (mean decrease in VAS pain of 3.2 mm (SD 16.7) for adalimumab vs
0.8 mm (SD 29.6) for placebo). The adjusted treatment effect was 0.7 mm (95% conﬁdence interval (CI)
9.3 to 8.0), P ¼ 0.87. No statistically signiﬁcant differences were found for any secondary outcomes.
Conclusion: Adalimumab did not show any effect on pain, synovitis or BMLs in patients with erosive hand
OA with MRI-detected synovitis as compared to placebo after 12 weeks.
Clinical trial registration number: ACTRN12612000791831.
© 2018 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.102
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Erosive hand osteoarthritis (OA) is considered a more inﬂam-
matory hand OA phenotype1. Patients are often difﬁcult to treat
with a high level of pain and disability. It is characterised by. Jones, Menzies Institute for
23, Hobart, Tasmania 7000,
.
ternational. Published by Elsevier L
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et al., A randomised double-
rial, Osteoarthritis and Cartilarticular cartilage damage, erosions and remodelling of the sub-
chondral bone2.
Tumour necrosis factor (TNF) a is a pro-inﬂammatory cytokine
produced by the synovial cells and chondrocytes and has been
implicated in the development and progression of OA3,4. This
makes TNF a a target for therapy to reduce pain and slow disease
progression; however, there is limited data on the effect of anti-TNF
a therapy in patients with hand OA5e8 and studies to date show
mixed ﬁndings with regard to clinical and structural progression. In
a randomised, double-blind, placebo-controlled trial over 6
months, Chevalier et al. reported that adalimumab treatment wastd. All rights reserved.
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119
blind placebo-controlled crossover trial of HUMira (adalimumab) for
age (2018), https://doi.org/10.1016/j.joca.2018.02.899
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not responding to analgesics and non-steroidal anti-inﬂammatory
drugs (NSAIDS)6. Another randomised controlled trial (RCT)
showed that 1-year of adalimumab treatment did not reduce
symptoms or erosive progression assessed by X-ray5. However,
post-hoc ﬁndings from this trial suggested that adalimumab ther-
apy halted erosive progression in a subset of hand OA patients with
clinically swollen joints at baseline5. Therefore, the aim of our study
was to assess the efﬁcacy of adalimumab (Humira, AbbVie Pty Ltd.),
40 mg subcutaneous injections every other week, for 12 weeks in a
randomised double-blind placebo-controlled crossover trial for
patients with erosive hand OA and evidence of magnetic resonance
imaging (MRI)-deﬁned synovitis.
Methods
Trial design
This study was a randomised double-blind placebo-controlled
crossover trial of adalimumab vs placebo. In a randomised cross-
over trial participants are assigned randomly to a sequence of
treatments and each participant serves as his/her own control in
estimating treatment effects9. As a result, fewer patients are
required for a crossover trial because it can achieve the same pre-
cision as a parallel group trial with less than half the sample size9.
Settings and locations
Participants were recruited from July 2013 to June 2015 through
advertising in local print media in Hobart, Tasmania, Australia, from
the private practice of a study investigator (GJ), and referrals from
other rheumatologists in Hobart. Participants attended clinics at
the Menzies Institute for Medical Research, Hobart, Tasmania.
Participants and screening procedure
Participants were ﬁrst screened over the telephone to determine
their interest and initial eligibility to participate in the trial, after
which they were invited to attend the study centre for a face-to-
face screening visit. Screening and clinical examinations were
performed by a rheumatologist (GJ) and two study nurses (MG and
KB). Participants had a clinical examination, supplied a blood
sample (for a range of laboratory tests, see Supplementary Table I),
had a chest X-ray (to exclude tuberculosis), a standard AP hand
radiograph and a hand MRI scan. This research was conducted in
compliance with the Declaration of Helsinki and was approved by
the Southern Tasmanian Health and Medical Human Research
Ethics Committee. All participants gave informed written consent.
Inclusion and exclusion criteria
We recruited participants aged >50 years, who met the Amer-
ican College of Rheumatology (ACR) criteria for hand OA10, and had
pain >50 on 100 mmvisual analogue scale (VAS), morning stiffness
>30 min, and 1 erosive joint on X-ray with synovitis present on
MRI. The exclusion criteria are outlined in Supplementary Table I.
Selection of the index joint
Following a clinical examination, hand X-ray and handMRI scan,
one joint was nominated as the index joint and this joint was
studied throughout the trial. First, clinical examinations and
screening of joint erosion on X-ray were performed by the principal
investigator (GJ), who is a rheumatologist with over 10 years of
experience reading X-rays. Patients who had joint erosion in their
clinically eligible joint were then sent for a 1.5 T non-contrast MRI
scan of their erosive joint to determine whether their erosive handPlease cite this article in press as: Aitken D, et al., A randomised double-
erosive hand OsteoaRthritis e the HUMOR trial, Osteoarthritis and CartilOAwas inﬂammatory, deﬁned by the presence of synovitis on MRI.
If >1 erosive joints were identiﬁed during initial screening themost
painful joint was used. Screening for the presence of synovitis was
undertaken by an experienced MRI reader (PB), a member of the
Outcome Measures in Rheumatology (OMERACT) MRI Inﬂamma-
tory arthritis group, and co-author of the OMERACT hand OA MRI
score (HOAMRIS)11.
Interventions
Patients were randomised to adalimumab (40 mg subcutaneous
injections every other week) or placebo for 12 weeks (treatment
period 1) followed by an 8-week washout and then the converse
treatment for 12 weeks (treatment period 2) (Fig. 1).
Outcomes
The primary outcome was change in VAS hand pain over 12
weeks. Secondary outcomes included change in the Australian/
Canadian Hand OA Index (AUSCAN) pain, function and stiffness
subscale from baseline to 4, 8 and 12 weeks, improvement in MRI-
detected synovitis and bone marrow lesions (BMLs) from baseline
to 12 weeks and change in the VAS pain subscale from baseline to 4
and 8 weeks.
Outcome measures
Pain, function and stiffness
Hand painwas measured using a 100mmVAS by asking “on this
line, where would you rate your pain, using the last 7 days as a
timeframe?” Hand pain, function and stiffness were measured us-
ing the AUSCAN12 on eight occasions (baseline, 4, 8 and 12 weeks of
each treatment period), using the last 48 h as a timeframe. AUSCAN
contains ﬁve items referring to hand pain, nine items relating to
difﬁculty with hand functions and one question on severity of
morning stiffness. The questions were scaled on a 100 mm VAS.
Total pain, function and stiffness subscale scores were calculated by
adding each of the items together. The possible range of scores was
0e500 for pain, 0e900 for function and 0e100 for stiffness.
MRI measures
Images of the index joint were acquired at baseline and 12
weeks of each treatment period with a 1.5 T whole-body magnetic
resonance unit (Siemens, Espree) using ﬁve sequences
(Supplementary Table II). One reader (IKH) read the baseline and
12-week MRIs with known time sequence for each treatment
period (blinded to treatment allocation). Synovitis and BMLs were
scored according to the OMERACT HOAMRIS11 or the OMERACT
thumb base OA MRI scoring system (TOMS)13. The reliability of
these scoring systems, as previously published, shows good to very
good ICC values11,13. Synovitis was assessed without the use of
gadolinium contrast. Thickened synovium were scored:
0¼ Normal, 1¼Mild, 2¼Moderate, 3¼ Severe. The 1e3 scores are
deﬁned by thirds of the presumed maximum volume of the syno-
vial compartment. BMLs were deﬁned as a signal characteristic
consistent with increased water content and with ill-deﬁned
margins within the trabecular bone and were scored as follows:
0 ¼ Normal, 1 ¼ Mild: 1e33% of bone volume, 2 ¼ Moderate:
34e66% of bone volume, 3 ¼ Severe: 67e100% of bone volume;
where “bone volume” refers to the proximal and distal part of the
joint combined. Changes in synovitis and BMLs over 12 weeks were
documented in 0.5 increments in case changes in these features
were present, but were not enough to be scored within the next
category. This is standard practice for performing longitudinal
measurements using these scoring systems11,13. Improvement inblind placebo-controlled crossover trial of HUMira (adalimumab) for
age (2018), https://doi.org/10.1016/j.joca.2018.02.899
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Fig. 1. Study ﬂow chart.
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YJOCA4184_proof ■ 8 March 2018 ■ 3/8synovitis or BMLs in the index joint was deﬁned as a decrease by 0.5
or more over the treatment period. What level reﬂects clinical
signiﬁcance is uncertain and has not yet been studied.
Concomitant medication/analgesic use
To maintain the pragmatic nature of the trial, there were no
restrictions with regard to concomitant analgesic medications
(including corticosteroids). All participants were allowed to
continue taking the medications that they were taking at their
screening visit for the duration of the trial. Participants were asked
to keep medications as stable as possible but if a participant
experienced an increase in pain requiring an increase in the dose of
analgesics the reason for the dose increase and the dose used was
documented. Medication usage was recorded at baseline, 4, 8 and
12 weeks of each treatment period.
Safety
Adverse events were deﬁned as any untoward event occurring
during the trial regardless of whether it was considered
medication-related. Serious adverse events were deﬁned as un-
planned hospital admissions, new cancer diagnoses or death during
the study.
Sample size
The power calculations were conducted considering the cross-
over trial design, where each participant experiences both treat-
ments assigned in random order. Enrolling a total of 40 patients
gave us 97% power, and 5% probability of type 1 error (alpha¼ 0.05)
to detect a 15 mm difference between adalimumab and placebo on
the VAS scale (SD of pain change 23.8 mm, based on in-house
data14). We assumed a correlation of 0.5 between readings made
on the same person.
Randomisation and sequence generation
Participants were allocated to either placebo or adalimumab at a
ratio of 1:1 based on computer-generated random numbers. The
random allocation sequence was automatically generated, and aPlease cite this article in press as: Aitken D, et al., A randomised double-
erosive hand OsteoaRthritis e the HUMOR trial, Osteoarthritis and Cartilsecurity protected central automated allocation procedure was
used to allocate participants to treatment arms. This was then used
by one author (LLL) who had no contact with participants to
dispense the syringes of allocated medication. Research nurses
enrolled participants in the trial, and then gave the allocated
medication to each individual patient. The active treatment and
placebo product were visually identical. Participants and staff
involved in patient care remained blinded to treatment allocation
throughout the trial.
Statistical methods
We used Stata 12.0 (StataCorp LP) for statistical analyses. Sta-
tistical signiﬁcance was set as a P-value <0.05. Analysis was by
intention to treat (ITT) as randomised in those receiving at least one
dose of the intervention in both treatment periods of the study.
Change in each outcomewas assessed using the difference between
the factor at baseline and each study visit (4, 8 and 12 weeks).
Baseline values were considered week 0 of treatment period 1 or 2
(see Fig. 1), as recommended for crossover trials9,15. The primary
outcome was change over 12 weeks as assessed by the VAS pain
scale.
For continuous outcomes, including change in VAS, AUSCAN
pain, function and stiffness subscales, treatment effects were
calculated using a repeated measures modelling approach adjust-
ing for the difference in each participants baseline value during
treatment period 1 and period 2 (i.e., adjusting for within-subject
baseline difference, method IV as recommended in Mehrotra16).
Data were checked for normality and for homogeneity of variance.
For categorical outcomes, including improvement in synovitis and
BMLs, c2 tests were used to examine differences in the proportion
of participants improving during each treatment period. We then
used log-binomial generalised estimating equations (GEE) analysis
to explore the risk of having an improvement in synovitis or BML
score in the active vs placebo groups. In all methods we clustered
on participant ID, and adjusted for the order in which the partici-
pant received their treatment (e.g., active then placebo, or placebo
then active).
c2 tests were used to compare numbers of adverse events.blind placebo-controlled crossover trial of HUMira (adalimumab) for
age (2018), https://doi.org/10.1016/j.joca.2018.02.899
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YJOCA4184_proof ■ 8 March 2018 ■ 4/8Therewas a discordance between the investigator who screened
the study patients for synovitis at enrolment and the scoring of
synovitis at the completion of the study. This resulted in four study
patients in the trial who did not have synovitis according to
HOAMRIS11 and/or TOMS13 scoring system. Analyses were repeated
with these four study participants excluded.
Results
Study participants
In total 51 participants attended screening for the study, of
whom eight were excluded (Fig. 1). The remaining 43 participants
were randomised to receive either adalimumab (n ¼ 18) or placebo
(n¼ 25) over treatment period 1. Therewere ﬁve study participants
that either withdrew during the study, or had missing primary
outcome data at 12 weeks.
Table I shows the baseline characteristics of study participants
by treatment received during treatment period 1. At baseline,
participants (n¼ 43) had amean age of 61 years (SD 8.4), mean BMI
of 28.9 (SD 4.2), mean VAS pain level of 63.6 (SD 17.7) out of 100
(indicating highly symptomatic disease), and 77% were women.
There were ﬁve study participants that were enrolled based on the
presence of erosive OA in the ﬁrst carpometacarpal (CMC1) joint.
The remaining participants had erosive OA in an interphalangeal
joint.
Outcomes
Data on the main outcomes are shown in Fig. 2 and Tables IIeV.
Primary outcome
At 12 weeks there was no difference in change of VAS pain be-
tween the groups (Table III). Mean decrease in VAS pain was
3.2 mm (SD 16.7) following adalimumab treatment vs 0.8 mm (SDTable I
Baseline characteristics of study participants, by treatment received during treat-
ment period 1
Baseline characteristics N Adalimumab N Placebo
Mean (SD) Mean (SD)
Age, years 18 63.1 (8.4) 25 61.2 (8.4)
Women, n (%) 18 15 (83) 25 18 (72)
Weight, kg 18 77.3 (12.9) 25 79.3 (15.0)
Height, cm 18 162.7 (8.7) 25 166.0 (8.3)
Body mass index, kg/m2 18 29.2 (3.8) 25 28.7 (4.5)
VAS pain score (0e100 mm) 18 63.9 (17.1) 25 63.4 (18.5)
AUSCAN pain subscale
score (0e500)
18 332 (98.5) 25 308.4 (96.4)
AUSCAN function subscale
score (0e900)
18 622.5 (181.9) 25 559.8 (165.6)
AUSCAN stiffness subscale
score (0e100)
18 73.7 (21.3) 25 66.9 (17.0)
Medication use
Paracetamol, n (%) 18 7 (39) 25 13 (52)
Average paracetamol dose, mg 7 1588 (1168) 13 1387 (954)
COX-2 inhibitors, n (%) 18 1 (6) 25 4 (16)
NSAIDS, n (%) 18 7 (39) 25 11 (44)
Number of pain medicines, n (%)
0 5 (28) 6 (24)
1 6 (33) 6 (24)
2 6 (33) 9 (36)
3 1 (6) 3 (12)
4 0 1 (4)
Synovitis (0e3) 18 1.3 (0.6) 24 1.2 (0.8)
BMLs (0e3) 18 1.0 (0.8) 25 1.3 (0.7)
COX-2 e Cyclooxygenase-2.
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was 0.7 mm (95% conﬁdence interval (CI) 9.3 to 8.0), P ¼ 0.87.
During treatment period 1, the adalimumab treated group had a
decrease in pain of 1.9 mm (Table II and Fig. 2). This group had an
increase in pain of 5.1 mm when they received placebo during
treatment period 2. During treatment period 1, the placebo treated
group had a decrease in pain of 5.0 mm. This group also had a
decrease in pain of 4.2 mmwhen they received adalimumab during
treatment period 2. These changes are small and are not considered
clinically important.
Secondary outcomes
No statistically signiﬁcant differences between adalimumab
treatment vs placebo treatment was seen for any secondary
symptomatic outcomes (Table III). There were small changes in
synovitis and BML scores in both groups and no signiﬁcant differ-
ence between the groups was observed (12% had an improvement
in synovitis score with adalimumab vs 10% with placebo (P¼ 0.63);
5% had an improvement in BML score with adalimumab vs 7% with
placebo (P ¼ 0.67) (Tables IV and V).
The results for the primary and secondary outcomes were un-
changed when the four patients without synovitis according to the
HOAMRIS11 and/or TOMS13 scoring system were excluded. The re-
sults were also unchanged when the ﬁve patients with erosive OA
in their CMC1 joint were excluded. Analgesic use throughout both
treatment periods was similar between groups (data not shown).
Adverse events
Adverse events were common, with 55% (n ¼ 23) of the placebo
group and 36% (n¼ 15) of the active group experiencing at least one
adverse event (Table VI). Differences in the total number of adverse
events and prevalence of events were not statistically signiﬁcant.
One participant had a serious adverse event with a non-elective
hospitalisation for treatment of cellulitis after cutting his/her
ﬁnger whilst in the adalimumab arm. Cellulitis was possibly caus-
ally related to the study drug.
Discussion
This RCT demonstrated that 12 weeks of treatment with adali-
mumab (40 mg subcutaneous injections every other week) was no
different to placebo to alleviate pain, synovitis or BMLs in patients
with erosive hand OA presenting with synovitis on MRI. The main
clinical outcome (change over 12 weeks as assessed by VAS pain)
was not different between the adalimumab and placebo groups.
Furthermore, no clinically or statistically signiﬁcant differences
were found for any of the secondary outcomes including patient-
reported outcomes and MRI-assessed structural abnormalities
(synovitis and BMLs). The results suggest that pain and inﬂam-
mation are not responsive to TNF a inhibition in this patient
population.
Anti-TNF a therapies have been very successful for treating pain
and structural disease progression in inﬂammatory arthritis such as
RA17. There is limited data on the effect of anti-TNF a therapy in
patients with hand OA5e8 and studies to date show mixed ﬁndings
with regard to clinical and structural progression. Evidence from
trial data has consistently shown that anti-TNF a therapy does not
improve symptoms in hand OA patients5e7 and the ﬁndings from
our study support this. In a randomised, double-blind, placebo-
controlled trial over 6 months, Chevalier et al. reported that adali-
mumab was not superior to placebo to alleviate pain in patients
with hand OA not responding to analgesics and NSAIDS6. Similarly
Verbruggen et al. showed that 1-year of adalimumab treatment didblind placebo-controlled crossover trial of HUMira (adalimumab) for
age (2018), https://doi.org/10.1016/j.joca.2018.02.899
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Fig. 2. Mean VAS pain score ± standard error over each 12-week treatment period.
Table II
Change in primary outcome (VAS pain score from baseline to 12weeks) over the two
treatment periods, based on the order in which they received the treatment
Treatment period Within-individual difference:
Activeeplacebo
Treatment sequence 1 2
Active then placebo
Mean (SE) 1.9 (3.4) 5.1 (8.5) 7.1 (8.6)
N 18 16 16
Placebo then active
Mean (SE) 5.0 (5.5) 4.2 (3.9) 1.2 (6.1)
N 23 23 22
Table III
Change in secondary outcomes by treatment group, and the adjusted treatment effect
N Placebo
Mean change (SD)
N Ac
M
Primary outcome
Change in VAS pain
Baseline to 12 weeks 39 0.8 (29.6) 41 3
Secondary outcomes
Change in VAS pain
Baseline to 4 weeks 41 4.1 (23.0) 40 6
Baseline to 8 weeks 39 5.2 (27.4) 41 7
Change in AUSCAN pain
Baseline to 4 weeks 42 12.9 (132.2) 41 3
Baseline to 8 weeks 41 18.7 (140.9) 41 4
Baseline to 12 weeks 40 4.9 (142.6) 41 2
Change in AUSCAN function
Baseline to 4 weeks 41 23.0 (169.5) 40 2
Baseline to 8 weeks 41 8.0 (198.7) 41 6
Baseline to 12 weeks 40 6.7 (215.8) 41 2
Change in AUSCAN stiffness
Baseline to 4 weeks 42 4.9 (25.7) 41 4
Baseline to 8 weeks 40 7.5 (25.9) 41 4
Baseline to 12 weeks 40 5.3 (28.8) 41 2
VAS range: 0e100; AUSCAN pain range: 0e500; AUSCAN function range: 0e900; AUSCA
* The treatment effect was adjusted for within-subject baseline difference and the or
placebo then active).
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Please cite this article in press as: Aitken D, et al., A randomised double-
erosive hand OsteoaRthritis e the HUMOR trial, Osteoarthritis and Cartilnot reduce symptoms including pain, stiffness, function and num-
ber of tender joints5.
Despite these previous negative trial ﬁndings, we hypothesised
that adalimumab may be effective in erosive hand OA when
inﬂammation was present (assessed in our study as MRI-detected
synovitis), given TNF a's pro-inﬂammatory role in the synovial
membrane18. In support of this, a previous study by Verbruggen
et al. suggested that adalimumab could halt erosive progression on
X-ray in a subset of patients with clinically swollen joints at base-
line5. However, despite selecting a sub-group of erosive hand OA
patients with synovitis, our trial failed to show an effect for pain or
structure (assessed as synovitis and BMLs on MRI as secondary
outcomes). The failure of adalimumab in painful hand OA may
indicate that TNF a may not be the right treatment target, even intive
ean change (SD)
N Adjusted treatment effect*
Mean difference (95% CI)
P-value
.2 (16.7) 41 0.7 (9.3 to 8.0) 0.87
.1 (22.7) 41 0.2 (8.1 to 7.6) 0.95
.7 (21.5) 41 0.4 (10.2 to 9.4) 0.94
1.0 (102.4) 41 1.9 (40.7 to 36.9) 0.92
1.5 (97.2) 41 4.3 (52.7 to 44.1) 0.86
0.9 (83.7) 41 8.7 (34.0 to 51.4) 0.68
1.9 (166.7) 41 23.2 (34.1 to 80.5) 0.42
1.4 (189.0) 41 19.4 (103.1 to 64.4) 0.64
3.0 (136.9) 41 18.5 (46.4 to 83.5) 0.57
.1 (23.2) 41 1.0 (8.7 to 10.7) 0.84
.3 (21.4) 41 4.9 (6.6 to 16.3) 0.39
.9 (22.4) 41 3.3 (5.5 to 12.1) 0.45
N stiffness range: 0e100.
der in which the participant received their treatment (e.g., active then placebo, or
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
blind placebo-controlled crossover trial of HUMira (adalimumab) for
age (2018), https://doi.org/10.1016/j.joca.2018.02.899
Q2
Table IV
Proportion of participants with an improvement in synovitis score from baseline to
12 weeks, the estimated treatment effect, and the proportion of participants with an
improvement based on the order in which they received the treatment
Treatment effect
Active, improved n (%) 5 (12%)
N 42
Placebo, improved n (%) 4 (10%)
N 41
Treatment effect*
Relative risk 1.2
95% CI 0.3e4.6
P-value P ¼ 0.74
Treatment period c2 P-value for difference
Treatment sequence 1 2
Active then placebo
Improved, n (%) 2 (11%) 0 (0%) N/A
N 18 17
Placebo then active
Improved, n (%) 4 (17%) 3 (13%) P ¼ 0.41
N 24 24
* The treatment effect was adjusted for the order in which the participant
received their treatment (e.g., active then placebo, or placebo then active).
Table V
Proportion of participants with an improvement in BML score from baseline to 12
weeks, the estimated treatment effect, and the proportion of participants with an
improvement based on the order in which they received the treatment
Treatment effect
Active, improved n (%) 2 (5%)
N 42
Placebo, improved n (%) 3 (7%)
N 41
Treatment effect*
Relative risk 0.7
95% CI 0.1e4.0
P-value 0.65
Treatment period c2 P-value for difference
Treatment sequence 1 2
Active then placebo
Improved, n (%) 0 (0%) 0 (0%) N/A
N 18 17
Placebo then active
Improved, n (%) 3 (13%) 2 (8%) 0.58
N 24 24
* The treatment effect was adjusted for the order in which the participant
received their treatment (e.g., active then placebo, or placebo then active).
Table VI
Prevalence and number of adverse events, by treatment received
Placebo
N ¼ 42
Active
N ¼ 42
Adverse events
Prevalence of at least one adverse event (n, %) 23 (54.8) 15 (35.7)
Total number of adverse events 32 27
Prevalence of (n, %):
Fall 0 2 (4.8)
Headache 5 (11.9) 3 (7.1)
Other joint pain 6 (14.3) 2 (4.8)
Insomnia 1 (2.4) 0
Upper respiratory tract infection 5 (11.9) 1 (2.4)
Sinusitis 2 (4.8) 1 (2.4)
Vertigo 0 2 (4.8)
Eczema 1 (2.4) 0
Increased hand pain/swelling 1 (2.4) 2 (4.8)
Sore eyes 2 (4.8) 0
Mouth ulcers 2 (4.8) 0
Nausea/vomiting 1 (2.4) 2 (4.8)
Fatigue 1 (2.4) 0
Hashimoto's disease 0 1 (2.4)
Hypertension 0 1 (2.4)
Rhinitis 0 1 (2.4)
Urinary tract infection 1 (2.4) 1 (2.4)
Reaction at site 0 3 (7.1)
Rash or itching 2 (4.8) 2 (4.8)
Shortness of breath 1 (2.4) 0
Shingles 0 1 (2.4)
Cataract removal 1 (2.4) 0
Gastroscopy 0 1 (2.4)
Cellulitis 0 1 (2.4)
Serious adverse events
Number of non-elective hospital admissions 0 1
Death 0 0
Cancer 0 0
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YJOCA4184_proof ■ 8 March 2018 ■ 6/8thosewith deﬁnite synovitis. Unlike RA, inﬂammation in OAmay be
present as a result of joint damage as opposed to primary immune
activation. It may not be driving the disease but rather represent a
consequence of the disease process. However, in contrast to this
theory, several studies have shown that synovitis on both MRI19
and ultrasound20 as well as clinical signs of inﬂammation21 pre-
dict future structural progression. Whether other features that are
co-occurring with synovitis are of larger importance than the sy-
novitis itself, should be further explored.
A treatment for erosive hand OA would need to improve
symptoms in order for it to be successful. Our study duration of 12
weeks to assess the effect on pain is sufﬁcient, as symptom modi-
ﬁcation should ideally be achieved by this time, otherwise patients
would not be motivated to continue treatment. Anti-TNF a therapy
in inﬂammatory arthritis such as PsA, RA and ankylosingPlease cite this article in press as: Aitken D, et al., A randomised double-
erosive hand OsteoaRthritis e the HUMOR trial, Osteoarthritis and Cartilspondylitis is associated with a rapid pain response (starting as
early as 2e4 weeks and reaching maximum efﬁciency by 8e12
weeks)17. It is possible that anti-TNF a therapy may exert differ-
ential effects on pain and structure. Our 12-week study may not
have been long enough to see structure modiﬁcation. Furthermore,
our crossover study design was not the ideal design to examine
changes in structure. The structural/imaging outcomes in our study
were synovitis and BMLs which likely reﬂect inﬂammation. Over 12
weeks we found only small changes in synovitis and BML scores
and no difference between the treatment vs placebo groups. A
successful therapy for erosive hand OA would ideally slow or pre-
vent the destructive subchondral remodelling that occurs in this
disease. Erosions and inﬂammation may represent different path-
ological processes22.
Hand OA trials have shown to have high placebo effects23, and
this was also the case in the previous studies that trialled adali-
mumab for hand OA6,7. In our trial we did not see large effects from
placebo, in fact, pain improvement in the VAS and AUSCAN pain
scales was well below the level of clinical relevance in both the
adalimumab and placebo groups. This could be due to the crossover
study design, as crossover trials are less prone to placebo effects24.
Advantages of a crossover study design include smaller sample
sizes over parallel designs, the elimination of between subject
variability as each participant serves as his/her own control and
enhanced recruitment as potential participants are aware they will
receive the active treatment at some point. However, there are
some considerations to this study design that need to be discussed.
First, as outlined above, crossover study designs are not ideal to
examine structural modiﬁcation. Second, crossover studies can be
limited because treatment from the ﬁrst period may have ablind placebo-controlled crossover trial of HUMira (adalimumab) for
age (2018), https://doi.org/10.1016/j.joca.2018.02.899
Q3
Q4
D. Aitken et al. / Osteoarthritis and Cartilage xxx (2018) 1e8 7
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
YJOCA4184_proof ■ 8 March 2018 ■ 7/8carryover effect9. To mitigate against this, we had an 8-week
washout, in which the treatment could ‘wear off’ before the
participant started the next treatment period. The average half-life
of adalimumab is 2 weeks, ranging between 10 and 20 days17.
While the optimal length of a washout period is unclear, for a drug
trial it is suggested to be between three and ﬁve times the half-life
of a drug. This would suggest that our washout period was
reasonable. Furthermore, our data do not show any carryover ef-
fects as there was very little improvement in pain, regardless of the
order they received the treatments. As recommended9,15, our
analysis accommodated the paired nature of the design and we
reported our data in a manner that facilitates understanding of any
carryover effects and missing data. Furthermore, the continuous
outcomes were adjusted for the difference in each participants
baseline value during treatment period 1 and period 2 (i.e.,
adjusted for within-subject baseline difference, method IV as rec-
ommended in Mehrotra16).
There are potential limitations to this study. First, synovitis was
assessed without the use of gadolinium contrast, whichmay be less
sensitive to detect changes in synovitis. Also, synovitis was mod-
erate at baseline and the level of inﬂammation may have been too
low to detect meaningful changes. Second, following a clinical ex-
amination, X-ray and MRI scan, one joint was nominated as the
index joint and this joint was studied throughout the trial. We did
not collect information about the number of other hand joints
involved (including the presence of tender or swollen joints) and
improvements may have occurred in these joints. Similarly the MRI
scans were only taken of the index joint therefore we could not
assess MRI changes in the other hand joints. Furthermore, we
included patients with both interphalangeal and thumb base OA. It
has been proposed that thumb base OA may be a unique pheno-
type. We did perform a sensitivity analysis, excluding the ﬁve pa-
tients that were included based on erosive CMC1 OA in their index
joint, and our results were unchanged. However, as we did not
collect information about other hand joints, we are unable to say
how many of our patients in total had CMC1 involvement. Third,
hand X-rays were performed for screening purposes only, and were
not scored to deﬁne disease severity in these patients. Therefore
the level of disease severity and phase of erosion damage25 was not
quantiﬁed and could not be examined in exploratory analysis.
Screening of erosions was performed by the principal investigator
(GJ), who is a rheumatologist with over 10 years of experience
reading X-rays.
Conclusions
Adalimumab did not show any effect on pain, synovitis or BMLs
in patients with erosive hand OA with MRI-detected synovitis, as
compared to placebo after 12 weeks treatment. This suggests that
pain and inﬂammation are not responsive toTNF a inhibition in this
patient population.
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